查看購物車
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治療市場規模、佔有率和成長分析：按藥物類別、疾病階段、通路管道、最終用戶和地區分類－2026-2033年產業預測
市場調查報告書
商品編碼
2064570

非酒精性脂肪性肝炎治療市場規模、佔有率和成長分析：按藥物類別、疾病階段、通路管道、最終用戶和地區分類－2026-2033年產業預測

Non-Alcoholic Steatohepatitis Treatment Market Size, Share, and Growth Analysis, By Drug Class (FXR Agonists, THR-B Agonists ), By Stage, By Distribution, By End-User, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球非酒精性脂肪性肝炎 (NASH) 治療市場價值為 35.2 億美元，預計到 2025 年將成長至 42.4 億美元，到 2033 年將成長至 188.5 億美元，在預測期（2026-2033 年）內成長至 188.5 億美元，在預測期（2026-2033 年）內複合年成長率為 20.32%。

非酒精性脂肪性肝炎 (NASH) 治療市場的成長主要受肝病發病率上升、大眾對 NASH 的認知度提高以及肥胖和 2 型糖尿病盛行率增加的推動。對標靶治療創新和肝病研究的大量投資進一步刺激了市場需求。臨床試驗的激增和藥物研發投入的增加表明，NASH 正被公認為一個獨立的醫學領域。儘管面臨治療成本高、早期診斷困難以及監管複雜等挑戰，但創新藥物候選物和聯合治療的研發工作正在加速。影像技術和非侵入性診斷測試的進步正在改善患者監測，而代謝藥物的新證據正在拓展治療選擇，並加速其在醫療保健市場的推廣應用。

全球非酒精性脂肪性肝炎 (NASH) 治療市場按藥物類別、疾病階段、分銷管道、最終用戶和地區進行細分。依藥物類別分類，市場分為 FXR促效劑、THR-B促效劑（利美沙酮）、SGLT2 抑制劑、GLP-1 受體促效劑和泛 PPAR促效劑。依疾病階段分類，市場分為「無肝硬化 NASH」和「伴肝硬化 NASH」。依分銷管道分類，市場分為「醫院藥局」及「專科藥局」。依最終用戶分類，市場分為「肝病診所」、「醫院」和「消化內科診所」。依地區分類，市場分為「北美」、「歐洲」、「亞太」、「拉丁美洲」以及「中東和非洲」。

全球非酒精性脂肪性肝炎 (NASH) 治療市場的成長要素

非侵入性影像技術、生物標記和先進診斷方法的發展顯著提高了非酒精性脂肪性肝炎的診斷和分期準確性，從而促進了更廣泛患者群體的篩檢、治療和臨床試驗參與。診斷清晰度的提高推動了個人化治療策略的製定，使醫療專業人員能夠更準確地識別新治療方法的適用人群，並提高了患者和醫生的接受度。此外，診斷準確性的提高帶來了更好的治療效果，鼓勵對治療進行更多投入，提高醫療機構的採用率，並最終推動全球市場的強勁成長。

全球非酒精性脂肪性肝炎治療市場面臨的限制因素

由於各地法規核准流程存在差異，全球非酒精性脂肪肝炎治療市場面臨嚴峻挑戰。這些差異為尋求治療方法核准的研發者帶來了不確定性，最終導致從臨床試驗到產品上市的時間延長。每個司法管轄區對證據、終點定義和上市後監測的要求各不相同，這使得研發過程更加複雜。這種複雜性不僅增加了申辦者的風險，也使商業性化上市和打入市場策略更加困難。因此，它可能阻礙投資、延遲產品上市，並對市場成長和患者可近性產生負面影響。

非酒精性脂肪性肝炎 (NASH) 治療的全球市場趨勢

全球非酒精性脂肪性肝炎 (NASH) 治療市場正經歷著向「精準醫療」的重大轉變，強調基於生物標記的診斷和個人化治療方案。相關人員日益重視開發能夠改善臨床療效並最大限度減少患者個別差異的個人化治療方法。為了充分利用這些進展，製藥公司和診斷公司之間的合作正在興起，為創新聯合治療和適應性臨床試驗設計鋪平了道路。此外，保險公司正將關注點轉向患者層面的價值，最終透過建立報銷機制，評估針對目標族群的治療方法和安全性，為 NASH 治療創造一個更專業和高效的環境。

目錄

介紹

  • 調查目的
  • 市場定義和範圍

調查方法

  • 研究過程
  • 二級資料和一級資料的方法
  • 市場規模估算方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態及展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特的分析和影響

關鍵市場分析

  • 關鍵成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 2025年市場魅力指數
  • PESTLE分析
  • 監理情勢

全球非酒精性脂肪性肝炎治療藥物市場規模：依藥物類別分類

  • FXR促效劑
  • THR-B促效劑（利美沙酮）
  • SGLT2抑制劑
  • GLP-1受體促效劑
  • 泛PPAR促效劑

全球非酒精性脂肪性肝炎治療市場規模：依階段分類

  • 非肝硬化性非酒精性脂肪性肝炎
  • 伴隨肝硬化的非酒精性脂肪性肝炎

全球非酒精性脂肪性肝炎治療市場規模：按分銷管道分類

  • 醫院藥房
  • 專科藥房

非酒精性脂肪性肝炎治療的全球市場規模：依最終用戶分類。

  • 肝病診所
  • 醫院
  • 胃腸病診所

全球非酒精性脂肪性肝炎治療市場規模：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭資訊

  • 前五大公司對比
  • 主要公司2025年的市場定位
  • 主要市場公司採取的策略
  • 近期市場趨勢
  • 企業市場占有率分析，2025 年
  • 主要公司的完整公司簡介
    • 公司詳情
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 銷售收入年比比較（2023-2025 年）

主要公司簡介

  • Madrigal Pharmaceuticals（Rezdiffra）
  • Novo Nordisk（Semaglutide）
  • Eli Lilly（Tirzepatide）
  • AstraZeneca
  • Intercept Pharmaceuticals
  • Genfit SA
  • Akero Therapeutics
  • 89bio Inc.
  • CymaBay Therapeutics
  • Viking Therapeutics
  • Inventiva SA
  • Metacrine
  • Axcella Health
  • Hepion Pharmaceuticals
  • Cirius Therapeutics
  • HighTide Biopharmaceutical
  • Pliant Therapeutics
  • Allergan（AbbVie）
  • Gilead Sciences
  • Boehringer Ingelheim

結論與建議

簡介目錄
Product Code: SQMIG35I2740

Global Non-Alcoholic Steatohepatitis Treatment Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 4.24 Billion in 2025 to USD 18.85 Billion by 2033, growing at a CAGR of 20.32% during the forecast period (2026-2033).

The market for non-alcoholic steatohepatitis (NASH) treatment is being fueled by the increasing rates of obesity and type 2 diabetes, alongside a rise in liver diseases and heightened awareness of NASH. Innovations in targeted therapeutics and substantial investments in liver disease research are further bolstering demand. The surge in clinical studies and heightened spending on drug development underscore the recognition of NASH as a distinct medical field. Despite challenges such as high treatment costs, early diagnosis difficulties, and regulatory complexities, the push for innovative drug candidates and combination therapies is gaining traction. Advancements in imaging techniques and non-invasive diagnostic tests are improving patient monitoring, while emerging evidence for metabolic drugs is expanding treatment options and encouraging acceptance in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Alcoholic Steatohepatitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Alcoholic Steatohepatitis Treatment Market Segments Analysis

Global non-alcoholic steatohepatitis treatment market is segmented by drug class, stage, distribution channel, end-user, and region. Based on drug class, the market is segmented into FXR Agonists, THR-B Agonists (Resmetirom), SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Pan-PPAR Agonists. Based on stage, the market is segmented into NASH without Cirrhosis and NASH with Cirrhosis. Based on distribution channel, the market is segmented into hospital pharmacies and specialty pharmacies. Based on end-user, the market is segmented into hepatology clinics, hospitals, and gastroenterology practices. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Non-Alcoholic Steatohepatitis Treatment Market

The development of noninvasive imaging techniques, biomarkers, and advanced diagnostics significantly enhances the accuracy of diagnosing and staging nonalcoholic steatohepatitis, facilitating the screening and treatment of a larger patient population, as well as their inclusion in clinical trials. This improved clarity in diagnosis promotes personalized treatment strategies, allowing healthcare providers to better identify candidates for emerging therapies, fostering greater acceptance among both patients and physicians. Additionally, the heightened diagnostic precision leads to improved therapeutic outcomes, encouraging further investment in treatments and increasing adoption rates across healthcare facilities, ultimately driving robust growth in the global market.

Restraints in the Global Non-Alcoholic Steatohepatitis Treatment Market

The global non-alcoholic steatohepatitis treatment market faces significant challenges due to the variations in regulatory approval processes across different regions. These discrepancies introduce an element of unpredictability for developers seeking approval for their therapies, ultimately slowing down the timeline from clinical trials to market readiness. Each jurisdiction has differing requirements for evidence, endpoint definitions, and extensive post-marketing surveillance, which complicates the development process. This complexity not only amplifies risks for sponsors but also complicates commercial launch and market access strategies. Consequently, it may deter investment and delay product introductions, adversely affecting market growth and patient accessibility.

Market Trends of the Global Non-Alcoholic Steatohepatitis Treatment Market

The Global Non-Alcoholic Steatohepatitis (NASH) Treatment market is witnessing a significant shift towards precision medicine, emphasizing personalized approaches that involve biomarker-driven diagnostics. Stakeholders are increasingly prioritizing the development of tailored treatment regimens that enhance clinical outcomes and minimize patient variability. Collaborations between drug developers and diagnostic firms are emerging to capitalize on these advancements, paving the way for innovative combination therapies and adaptive clinical trial designs. Furthermore, payers are shifting their focus toward patient-level value, creating reimbursement pathways that reward effective and predictably safe treatments in targeted populations, ultimately shaping a more specialized and effective landscape in NASH therapies.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • FXR Agonists
  • THR-B Agonists (Resmetirom)
  • SGLT2 Inhibitors
  • GLP-1 Receptor Agonists
  • Pan-PPAR Agonists

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Stage & CAGR (2026-2033)

  • Market Overview
  • NASH without Cirrhosis
  • NASH with Cirrhosis

Global Non-Alcoholic Steatohepatitis Treatment Market Size by Distribution & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacies
  • Specialty Pharmacies

Global Non-Alcoholic Steatohepatitis Treatment Market Size by End-User & CAGR (2026-2033)

  • Market Overview
  • Hepatology Clinics
  • Hospitals
  • Gastroenterology Practices

Global Non-Alcoholic Steatohepatitis Treatment Market Size & CAGR (2026-2033)

  • North America (Drug Class, Stage, Distribution, End-User)
    • US
    • Canada
  • Europe (Drug Class, Stage, Distribution, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Drug Class, Stage, Distribution, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Drug Class, Stage, Distribution, End-User)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Stage, Distribution, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Madrigal Pharmaceuticals (Rezdiffra)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novo Nordisk (Semaglutide)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly (Tirzepatide)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Intercept Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genfit SA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Akero Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • 89bio Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CymaBay Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viking Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Inventiva SA
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Metacrine
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Axcella Health
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hepion Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cirius Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HighTide Biopharmaceutical
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pliant Therapeutics
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan (AbbVie)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations